| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Department of Cell Research and Immunology, George S. Wise Faculty of Life Sciences, Tel-Aviv University, Tel-Aviv 69978 [G. L., S. S., I. K., A. B-B.]; Department of Surgery A, Tel-Aviv Sourasky Medical Center, Tel-Aviv 64239 [O. K.]; Department of Pathology, Ramat Marpe Hospital, Ramat Gan 49631 [S. E., D. N.]; Institute of Pathology, Diagnostic and Research Cancer Center, Tel-Aviv Sourasky Medical Center, Tel-Aviv 64239 [B. L-M.]; and Department of Oncology, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 69978 [S. C.], Israel
Breast carcinoma is the most common malignant disease among women and the second most lethal one. In search for a better understanding of the role of cellular mediators in the progression of this disease, we investigated the potential involvement of the CC chemokine Regulated on Activation, Normal T Cell Expressed and Secreted (RANTES) in breast carcinoma progression. To this end, RANTES expression was determined in breast tumor cell lines and in sections of breast carcinomas, followed by analysis of the incidence and intensity of its expression in different stages of the disease. Our study reveals that high and physiologically relevant levels of RANTES are constitutively produced by T47D and MCF-7 breast tumor cell lines. Analysis of RANTES expression in sections of breast carcinomas demonstrates a high incidence of RANTES expression in epithelial tumor cells; the chemokine was expressed in 74% of the sections. RANTES expression was rarely detected in normal duct epithelial cells or in epithelial cells that constitute benign breast lumps, which were located in proximity to tumor cells. High incidence and intensity of RANTES expression were detected in sections of most of the patients with stage II and stage III of the disease (expression was detected in 83 and 83.3%, respectively), whereas RANTES was expressed at a lower incidence and intensity in sections of patients with stage I of breast carcinoma (55% of the cases). Most importantly, the expression of RANTES was minimally detected in sections of patients diagnosed with benign breast disorders and of women that underwent reduction mammoplasty (15.4% of the cases). These results indicate that the expression of RANTES is directly correlated with a more advanced stage of disease, suggesting that RANTES may be involved in breast cancer progression. Moreover, it is possible that in patients diagnosed with benign breast disorders, RANTES expression may be indicative of an ongoing, but as yet undetectable, malignant process.
This article has been cited by other articles:
![]() |
H. Laubli, K.-S. Spanaus, and L. Borsig Selectin-mediated activation of endothelial cells induces expression of CCL5 and promotes metastasis through recruitment of monocytes Blood, November 12, 2009; 114(20): 4583 - 4591. [Abstract] [Full Text] [PDF] |
||||
![]() |
F.-Y. Wu, Z.-L. Ou, L.-Y. Feng, J.-M. Luo, L.-P. Wang, Z.-Z. Shen, and Z.-M. Shao Chemokine Decoy Receptor D6 Plays a Negative Role in Human Breast Cancer Mol. Cancer Res., August 1, 2008; 6(8): 1276 - 1288. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Datta, J. A. Flaxenburg, S. Laxmanan, C. Geehan, M. Grimm, A. M. Waaga-Gasser, D. M. Briscoe, and S. Pal Ras-induced Modulation of CXCL10 and Its Receptor Splice Variant CXCR3-B in MDA-MB-435 and MCF-7 Cells: Relevance for the Development of Human Breast Cancer Cancer Res., October 1, 2006; 66(19): 9509 - 9518. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Lamagna, M. Aurrand-Lions, and B. A. Imhof Dual role of macrophages in tumor growth and angiogenesis J. Leukoc. Biol., October 1, 2006; 80(4): 705 - 713. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Yaal-Hahoshen, S. Shina, L. Leider-Trejo, I. Barnea, E. L. Shabtai, E. Azenshtein, I. Greenberg, I. Keydar, and A. Ben-Baruch The Chemokine CCL5 as a Potential Prognostic Factor Predicting Disease Progression in Stage II Breast Cancer Patients Clin. Cancer Res., August 1, 2006; 12(15): 4474 - 4480. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Borczuk, H. K. Kim, H. A. Yegen, R. A. Friedman, and C. A. Powell Lung Adenocarcinoma Global Profiling Identifies Type II Transforming Growth Factor-{beta} Receptor as a Repressor of Invasiveness Am. J. Respir. Crit. Care Med., September 15, 2005; 172(6): 729 - 737. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. W. van Deventer, W. O'Connor Jr., W. J. Brickey, R. M. Aris, J. P.Y. Ting, and J. S. Serody C-C Chemokine Receptor 5 on Stromal Cells Promotes Pulmonary Metastasis Cancer Res., April 15, 2005; 65(8): 3374 - 3379. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Murdoch, A. Giannoudis, and C. E. Lewis Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues Blood, October 15, 2004; 104(8): 2224 - 2234. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Lavergne, C. Combadiere, M. Iga, A. Boissonnas, O. Bonduelle, M. Maho, P. Debre, and B. Combadiere Intratumoral CC Chemokine Ligand 5 Overexpression Delays Tumor Growth and Increases Tumor Cell Infiltration J. Immunol., September 15, 2004; 173(6): 3755 - 3762. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Robinson, K. A. Scott, J. L. Wilson, R. G. Thompson, A. E. I. Proudfoot, and F. R. Balkwill A Chemokine Receptor Antagonist Inhibits Experimental Breast Tumor Growth Cancer Res., December 1, 2003; 63(23): 8360 - 8365. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Manes, E. Mira, R. Colomer, S. Montero, L. M. Real, C. Gomez-Mouton, S. Jimenez-Baranda, A. Garzon, R. A. Lacalle, K. Harshman, et al. CCR5 Expression Influences the Progression of Human Breast Cancer in a p53-dependent Manner J. Exp. Med., November 3, 2003; 198(9): 1381 - 1389. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Crittenden, M. Gough, K. Harrington, K. Olivier, J. Thompson, and R. G. Vile Expression of Inflammatory Chemokines Combined with Local Tumor Destruction Enhances Tumor Regression and Long-term Immunity Cancer Res., September 1, 2003; 63(17): 5505 - 5512. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Wolf, I. Clark-Lewis, C. Buri, H. Langen, M. Lis, and L. Mazzucchelli Cathepsin D Specifically Cleaves the Chemokines Macrophage Inflammatory Protein-1{alpha}, Macrophage Inflammatory Protein-1{beta}, and SLC That Are Expressed in Human Breast Cancer Am. J. Pathol., April 1, 2003; 162(4): 1183 - 1190. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. De Bleecker, B. De Paepe, I. E. Vanwalleghem, and J. M. Schroder Differential expression of chemokines in inflammatory myopathies Neurology, June 25, 2002; 58(12): 1779 - 1785. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Lin, Y. Nagai, R. Sladek, Y. Bastien, J. Ho, K. Petrecca, G. Sotiropoulou, E. P. Diamandis, T. J. Hudson, and J. H. White Expression Profiling in Squamous Carcinoma Cells Reveals Pleiotropic Effects of Vitamin D3 Analog EB1089 Signaling on Cell Proliferation, Differentiation, and Immune System Regulation Mol. Endocrinol., June 1, 2002; 16(6): 1243 - 1256. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Huang, Y. Lin, C. C. Wang, J. Gano, B. Lin, Q. Shi, A. Boynton, J. Burke, and R.-P. Huang Connexin 43 Suppresses Human Glioblastoma Cell Growth by Down-Regulation of Monocyte Chemotactic Protein 1, as Discovered Using Protein Array Technology Cancer Res., May 1, 2002; 62(10): 2806 - 2812. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Azenshtein, G. Luboshits, S. Shina, E. Neumark, D. Shahbazian, M. Weil, N. Wigler, I. Keydar, and A. Ben-Baruch The CC Chemokine RANTES in Breast Carcinoma Progression: Regulation of Expression and Potential Mechanisms of Promalignant Activity Cancer Res., February 1, 2002; 62(4): 1093 - 1102. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Kamath, A. Meydani, F. Foss, and A. Kuliopulos Signaling from Protease-activated Receptor-1 Inhibits Migration and Invasion of Breast Cancer Cells Cancer Res., August 1, 2001; 61(15): 5933 - 5940. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Scotton, J. L. Wilson, D. Milliken, G. Stamp, and F. R. Balkwill Epithelial Cancer Cell Migration: A Role for Chemokine Receptors? Cancer Res., July 1, 2001; 61(13): 4961 - 4965. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Simchen, I. Lehmann, D. Sittig, M. Steinert, and G. Aust Expression and Regulation of Regulated on Activation, Normal T Cells Expressed and Secreted in Thyroid Tissue of Patients with Graves' Disease and Thyroid Autonomy and in Thyroid-Derived Cell Populations J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4758 - 4764. [Abstract] [Full Text] |
||||
![]() |
G. Aust, C. Simchen, U. Heider, F. A. Hmeidan, V. Blumenauer, and K. Spanel-Borowski Eosinophils in the human corpus luteum: the role of RANTES and eotaxin in eosinophil attraction into periovulatory structures Mol. Hum. Reprod., December 1, 2000; 6(12): 1085 - 1091. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |